Informational only — Not medical advice. Always consult a licensed healthcare provider.

MedBD
বাং
Community data Updated 2 months ago
🌐 বাংলায় দেখুন

Indications

Inophos helps lower phosphorus levels in the blood of patients with end-stage renal disease (ESRD).

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Sevelamer Hydrochloride is used to control serum phosphorus levels in patients with chronic kidney disease (CKD) who are on dialysis. When serum phosphorus levels rise and hyperphosphatemia goes uncontrolled, it can lead to secondary hyperparathyroidism, renal bone disease, calcification of vascular and nonvascular tissues, and cardiovascular disease. Sevelamer Hydrochloride is a phosphate binder that is free of calcium and aluminium and is not absorbed by the body, so it does not carry the risk of calcium or aluminium toxicity. Taken with meals, it works by inhibiting the intestinal absorption of phosphate from food.

Pregnancy & Breastfeeding

Pregnancy Category C. There haven't been any well-controlled studies looking at Sevelamer's use in breastfeeding mothers. It should only be used while breastfeeding if the potential benefit is judged to outweigh the potential risk.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Sevelamer's recommended starting dose for patients not already taking a phosphate binder is 800 to 1600 mg, given as two to four 400 mg Sevelamer tablets with meals, based on the serum phosphorus level. The recommendation for Renophos 400 in patients with hyperphosphatemia is given below. Starting dose of Renophos for dialysis patients not taking any phosphate binder: for serum phosphorus above 5.5 and below 7.5 mg/dL, 800 mg (2 tablets) three times daily with meals; for serum phosphorus 7.5 up to 9.0 mg/dL, 1200 mg (3 tablets) three times daily with meals; for serum phosphorus 9.0 mg/dL or above, 1600 mg (4 tablets) three times daily with meals. Starting dose for dialysis patients switching from calcium acetate to Sevelamer: calcium acetate 667 mg (1 tablet) corresponds to Sevelamer 800 mg (2 tablets); calcium acetate 1334 mg (2 tablets) corresponds to Sevelamer 1200 mg (3 tablets); calcium acetate 2001 mg (3 tablets) corresponds to Sevelamer 2000 mg (5 tablets). Dose titration guideline: if serum phosphorus is above 5.5 mg/dL, increase the dose by 400 mg (1 tablet) per meal at two week intervals; if serum phosphorus is between 3.5 and 5.5 mg/dL, maintain the current dose; if serum phosphorus is below 3.5 mg/dL, decrease the dose by 400 mg (1 tablet) per meal. Dose titration for all patients taking Sevelamer: the dosage should be adjusted based on the serum phosphorus concentration, with a goal of lowering serum phosphorus to 5.5 mg/dL or less. The dose may be increased or decreased by one tablet per meal at two week intervals as necessary.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.